Skip to content

Study · Not a test of the peptide alone · 2026

3 results

Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.

Cheng PL, Chang HC

Diabetes research and clinical practice18 May 2026

PMID42155605 (opens in a new tab)DOI10.1016/j.diabres.2026.113333 (opens in a new tab)PepBankPUB-42155605
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In a meta-analysis of interventional studies, pooled GLP-1 receptor agonist users had a higher risk of hair loss than placebo users.

    In plain wordsIn a pooled analysis of GLP-1 drugs as a class, users had a higher risk of hair loss than people on placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseHair loss
    Study

    n = 4,114

    Comparator
    Placebo
    Outcome group
    Skin and hair · Skin and wound

    Measurements

    Risk ratio
    3.252
    pooled GLP-1 RA vs placebo

    Source sentences

    Summary
    The pooled analysis revealed a significantly higher risk of hair loss in GLP-1 RA users than in placebo users (risk ratio [RR]: 3.252; 95% confidence interval [CI]: 1.437 to 7.358).
    1 context sentence
    Summary · context
    We included randomized controlled trials (RCTs) or prospective nonrandomized interventional studies that reported hair loss following GLP-1 RA therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In pooled randomized trials of adults with overweight or obesity, GLP-1 receptor agonist users had a higher risk of hair loss than placebo users.

    In plain wordsIn pooled trials of GLP-1 drugs as a class in people with overweight or obesity, users had a higher risk of hair loss than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseHair loss
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Skin and hair · Skin and wound

    Measurements

    Risk ratio
    3.587
    pooled GLP-1 RA vs placebo, RCTs in overweight or obesity

    Source sentences

    Summary
    The significant results persisted even when the analysis was restricted to RCTs focusing on patients with overweight or obesity (RR: 3.587; 95% CI: 2.100 to 6.124).
    1 context sentence
    Summary · context
    We included randomized controlled trials (RCTs) or prospective nonrandomized interventional studies that reported hair loss following GLP-1 RA therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In a single-arm meta-analysis, the pooled event rate of hair loss with GLP-1 receptor agonist therapy was 3.9%.

    In plain wordsAcross studies of GLP-1 drugs as a class, about 3.9% of users had hair loss.

    Peptide
    Semaglutide
    Outcome
    Not applicableHair loss
    Study

    n: not reported in source

    Outcome group
    Skin and hair · Skin and wound

    Measurements

    Hair loss event rate
    3.9%
    pooled GLP-1 RA, single-arm analysis

    Source sentences

    Summary
    Furthermore, a single-arm analysis revealed that the event rate of hair loss following GLP-1 RA therapy was 3.9%.
    1 context sentence
    Summary · context
    We included randomized controlled trials (RCTs) or prospective nonrandomized interventional studies that reported hair loss following GLP-1 RA therapy.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.